Ethiquinium chloride, an asymmetric bisquaternary ammonium salt, in the therapy of hypertension.

Abstract

EXPERIENCE accumulated with the use of hypotensive agents over the past decade has suggested that prolonged, meticulous pharmacotherapy may be associated with an alteration in the basic process causing hypertension.1 These data have prompted the conviction that every patient with documented high blood pressure should be offered a trial of therapy.2 "Chemical sympathectomy" with hexamethonium and pentolinium derivatives has attracted particular attention among the various modalities of treatment. Structurally, these compounds are symmetric bisquaternary ammonium salts, and their efficacy led to the exploration of possible vasodepressor properties of the closely related asymmetric bisquaternary ammonium compounds, of which chlorisondamine3 is the . . .